For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of BridgeBio Pharma Inc (NASDAQ: BBIO) closed at $51.32 in the last session, up 0.27% from day before closing price of $51.18. In other words, the price has increased by $0.27 from its previous closing price. On the day, 1.95 million shares were traded. BBIO stock price reached its highest trading level at $51.66 during the session, while it also had its lowest trading level at $50.6.
Ratios:
We take a closer look at BBIO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.08 and its Current Ratio is at 5.19.
On July 21, 2025, Truist started tracking the stock assigning a Buy rating and target price of $66.
On July 14, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $70.Jefferies initiated its Buy rating on July 14, 2025, with a $70 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 08 ’25 when HOMCY CHARLES J sold 250,000 shares for $46.05 per share. The transaction valued at 11,512,443 led to the insider holds 966,674 shares of the business.
HOMCY CHARLES J sold 50,000 shares of BBIO for $2,400,000 on Aug 11 ’25. The Director now owns 916,674 shares after completing the transaction at $48.00 per share. On Aug 07 ’25, another insider, Apuli Maricel, who serves as the Chief Accounting Officer of the company, sold 1,000 shares for $45.44 each. As a result, the insider received 45,440 and left with 141,859 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 9810792448 and an Enterprise Value of 10921682944. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.60. Its current Enterprise Value per Revenue stands at 46.315 whereas that against EBITDA is -17.51.
Stock Price History:
The Beta on a monthly basis for BBIO is 1.25, which has changed by 1.0389352 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, BBIO has reached a high of $51.86, while it has fallen to a 52-week low of $21.72. The 50-Day Moving Average of the stock is 14.61%, while the 200-Day Moving Average is calculated to be 46.79%.
Shares Statistics:
According to the various share statistics, BBIO traded on average about 2.89M shares per day over the past 3-months and 3845510 shares per day over the past 10 days. A total of 191.16M shares are outstanding, with a floating share count of 162.08M. Insiders hold about 15.24% of the company’s shares, while institutions hold 89.49% stake in the company. Shares short for BBIO as of 1753920000 were 18519082 with a Short Ratio of 6.42, compared to 1751241600 on 21834552. Therefore, it implies a Short% of Shares Outstanding of 18519082 and a Short% of Float of 16.259999999999998.
Earnings Estimates
The current rating of BridgeBio Pharma Inc (BBIO) is the result of assessments by 4.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.31 and low estimates of -$0.94.
Analysts are recommending an EPS of between -$2.1 and -$3.82 for the fiscal current year, implying an average EPS of -$2.59. EPS for the following year is -$1.58, with 6.0 analysts recommending between -$0.97 and -$2.22.
Revenue Estimates
According to 17 analysts, the current quarter’s revenue is expected to be $109.29M. It ranges from a high estimate of $140.5M to a low estimate of $85.72M. As of the current estimate, BridgeBio Pharma Inc’s year-ago sales were $2.73MFor the next quarter, 17 analysts are estimating revenue of $127.52M. There is a high estimate of $177M for the next quarter, whereas the lowest estimate is $52.37M.
A total of 20 analysts have provided revenue estimates for BBIO’s current fiscal year. The highest revenue estimate was $545.13M, while the lowest revenue estimate was $412.03M, resulting in an average revenue estimate of $473.05M. In the same quarter a year ago, actual revenue was $221.9MBased on 19 analysts’ estimates, the company’s revenue will be $771.05M in the next fiscal year. The high estimate is $1.12B and the low estimate is $536.11M.
